CSIMarket
 
Tarsus Pharmaceuticals Inc   (NASDAQ: TARS)
Other Ticker:  
 
 
Price: $51.2200 $-0.54 -1.043%
Day's High: $52.005 Week Perf: -10.05 %
Day's Low: $ 49.86 30 Day Perf: -2.79 %
Volume (M): 515 52 Wk High: $ 57.28
Volume (M$): $ 26,378 52 Wk Avg: $36.91
Open: $51.47 52 Wk Low: $20.08



 Market Capitalization (Millions $) 1,966
 Shares Outstanding (Millions) 38
 Employees 25
 Revenues (TTM) (Millions $) 130
 Net Income (TTM) (Millions $) -134
 Cash Flow (TTM) (Millions $) -50
 Capital Exp. (TTM) (Millions $) 2

Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for ophthalmic diseases. The company aims to address unmet needs in the field of eye health by focusing on ocular surface and anterior segment conditions. Tarsus Pharmaceuticals is known for its expertise in the development of novel, small molecule therapeutics that target specific pathways involved in these diseases. The company's goal is to provide effective and safe treatment options to improve the lives of patients suffering from various eye disorders.


   Company Address: 15440 Laguna Canyon Road, Suite 160 Irvine 92618 CA
   Company Phone Number: 418-1801   Stock Exchange / Ticker: NASDAQ TARS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALDX        3.94% 
BSTG        14.1% 
EYEN   -24.37%    
EYPT   -19.49%    
OCUL   -8.49%    
• View Complete Report
   



Product Service News

Tarsus Pharmaceuticals Sets Sights on Ocular Rosacea with Promising Pipeline Developments

Published Mon, Jan 13 2025 1:56 PM UTC

In an ambitious update, Tarsus Pharmaceuticals delineated its strategic progress toward establishing ocular rosacea as a pivotal therapeutic opportunity within the eye care sector, targeting launch dates as early as 2025. The definitive plan includes advancing their novel treatment candidate, TP-04 (lotilaner ophthalmic gel), through the initiation of a Phase 2 clinical stud...

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc. Struggles to Turn Revenue Surge into Profit in Q1 2024

Tarsus Pharmaceuticals Inc, a pharmaceutical company focused on revolutionizing treatment for patients, particularly in the field of eye care, has recently seen positive stock market performance. Over the last five trading days, Tarsus Pharmaceuticals Inc shares recorded a solid gain of 7.85%. This positive growth brings the share price to a 4.18% increase during the second quarter of 2024.
The company's shares are trending higher and are only 7.5% away from its 52-week high. This indicates a positive market sentiment and potential for further growth.

Product Service News

Tarsus Pharmaceuticals Strengthens Financial Position with $200 Million Financing Commitment from Pharmakon Advisors

Published Tue, Apr 23 2024 12:30 PM UTC

Tarsus Pharmaceuticals Secures $200 Million Financing Commitment from Pharmakon, Bolstering Financial PositionIRVINE, Calif., April 23, 2024 - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company dedicated to addressing unmet medical needs and leveraging innovative science and technology to revolutionize patient care, has announced today its successful acquisition of $200 ...

Shares

Tarsus Pharmaceuticals Secures $100 Million Public Offering to Drive Innovation in Eye Care Sector

Published Fri, Mar 1 2024 5:08 AM UTC

Tarsus Pharmaceuticals Announces Pricing of $100 Million Public Offering
In a press release on March 1, 2024, Tarsus Pharmaceuticals, Inc. revealed the pricing of its underwritten public offering of 2,812,500 shares of common stock at $32.00 per share, as well as pre-funded warrants for an additional 312,500 shares at $31.9999. The company also granted the underwriters a...

Financing Agreement

Tarsus Pharmaceuticals Inc. Sets Stage for Transformational Growth with $100 Million Public Offering

Published Thu, Feb 29 2024 9:38 PM UTC



Tarsus Pharmaceuticals Inc., a pioneering biopharmaceutical company with a focus on transforming treatment options for patients, especially in the field of eye care, has announced the initiation of an underwritten public offering. The company aims to raise a substantial $100.0 million through the sale of its common stock or pre-funded warrants. This move comes as T...







Tarsus Pharmaceuticals Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com